Multiple myeloma remains the second most common hematologic malignancy in the United States, after non-Hodgkin lymphoma. Historically, multiple myeloma has been a difficult and frustrating disease for patients and their health care providers. Since the reintroduction of thalidomide(Drug information on thalidomide) and the development of lenalidomide and bortezomib(Drug information on bortezomib), outcomes have improved considerably, particularly when these newer agents are combined with conventional chemotherapeutic agents or with each other. Obviously, it is vitally important for today’s health care providers to understand the newer agents; however, this is a challenge, because the drugs have multiple functions (eg, antiangiogenesis, immunomodulation, proteasome inhibition), have different toxicity profiles, and can be used in myriad combinations and sequences. Hematologists/oncologists have indicated a need to know more about the choice of first-line, second-line, and third-line therapies; the management of the side effects of the new agents; the role and timing of stem cell transplantation in the era of the new therapies; the guidelines for maintenance therapy; and newer therapeutic combinations for the future treatment of myeloma.
This activity is designed for physicians, pharmacists, physician assistants, nurses, nurse practitioners, and other health care professionals who have an interest in enhancing their knowledge and understanding of the management of multiple myeloma.
Upon completion of this activity, participants should be able to:
• Determine the best treatment options for newly diagnosed patients with multiple myeloma based on recent research data
• Recognize and choose the most appropriate treatment options for patients with relapsed and refractory multiple myeloma based on recent research data
• Assess the need for maintenance therapy in multiple myeloma and propose appropriate options for maintenance therapy
• Evaluate the current importance of assessing patients with multiple myeloma at risk, especially in the face of emerging and novel agents, and integrate this knowledge into a management plan
• Describe the most appropriate techniques for monitoring multiple myeloma
• Formulate evidence-based management plans for patients with multiple myeloma based upon their age, risk, and comorbidities
• Outline the most suitable goals for treatment of multiple myeloma as therapeutic options evolve
This activity is eligible for credit through March 15, 2011. After this date, this activity will expire and no further credit will be awarded.
Expected time to complete this activity as designed: 2.5 hours
There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. The certificate will be mailed 4 weeks after receipt of a completed, qualified form.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is acceptable for 2.5 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-10-240-H01-P. Knowledge-based CPE activity.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067, is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.5 contact hours. Program Number: 10-240-232
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE, and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CE activity are required to disclose any relevant financial relationships they may have or have had within the past 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly, the following disclosures were made.
The presenting faculty reported the following:
• Dr. Anderson is on the advisory boards for and has received research support and honoraria from Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis AG.
• Ms. Doss is on the speakers’ bureau for Celgene Corporation and Millennium Pharmaceuticals, Inc.
• Dr. Ghobrial is on the advisory board for Celgene Corporation, and the speakers’ bureau for Celgene, Millennium Pharmaceuticals, Inc., and Novartis AG; and has received honoraria from Celgene, Millennium, and Novartis.
• Dr. Jagannath has received consultant fees from Celgene Corporation, Merck & Co., Inc., and Millennium Pharmaceuticals, Inc.
• Dr. Mark is on the speakers’ bureau for Celgene Corporation and Millennium Pharmaceuticals, Inc.
• Dr. Mitsiades has received research support from Amgen Inc., AVEO Pharmaceuticals, Inc., EMD Serono, Inc., OSI Pharmaceuticals, Inc., and Sunesis Pharmaceuticals, Inc., and has received honoraria from Bristol-Myers Squibb, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Novartis AG.
• Dr. Munshi is on the advisory board for Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis AG.
• Dr. Niesvizky is on the speakers’ bureau for Celgene Corporation, Millennium Pharmaceuticals, Inc., Centocor Ortho Biotech Inc., and Onyx Pharmaceuticals.
• Dr. Richardson is on the advisory board for Celgene Corporation and Millennium Pharmaceuticals, Inc.
• Dr. Schlossman is on the speakers’ bureau for Celgene Corporation and Millennium Pharmaceuticals, Inc.
• Dr. Stadtmauer is on the speakers’ bureau and advisory board for Celgene Corporation and Millennium Pharmaceuticals, Inc.
• Ms. Colson has served on advisory boards for Millennium Pharmaceuticals, Inc.
• Dr. Coleman, Dr. Laubach, Ms. McKenney, Ms. Noonan, and Ms. Warren have no potential conflicts of interest to disclose.
The individuals listed below from MediCom Worldwide, Inc., reported the following for this activity: Joan Meyer, executive director; Jacqui Brooks, MBBCH, MRCPsych, VP medical education; Gene Tombler, PhD, medical director; and Faith Reidenbach, medical writer, have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Jagannath and Niesvizky indicated that their material would not include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for any use in the United States.
Drs. Richardson and Stadtmauer indicated that their material would include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for certain uses in the United States.
CONFLICT OF INTEREST RESOLUTION
To resolve identified conflicts of interest, the educational content was fully peer reviewed by members of the MediCom Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.